細胞ベースのアッセイ市場は、2025年の178億4000万米ドルから2030年までに275億5000万米ドルに成長し、予測期間中に9.1%のCAGRで成長すると予想されています。細胞ベースのアッセイ市場の主要なプレーヤーには、BD(米国)、Thermo Fisher Scientific Inc.(米国)、Danaher Corporation(米国)、Merck KGaA(ドイツ)、Agilent Technologies、Inc.(米国)、Lonza(スイス)、Charles River Laboratories(米国)、Bio-Rad Laboratories、Inc.(米国)、Revvity(米国)、Sartorius AG(ドイツ)、Corning Incorporated(米国)、Promega Corporation(米国)、Cell Signaling Technology、Inc.(米国)、Eurofins Scientific(ルクセンブルク)、Enzo Biochem、 Inc.(米国)、カルナバイオサイエンス株式会社 (日本)、Intertek Group Plc(英国)、BICO(スウェーデン)、Cell Biolabs, Inc.(米国)、Reaction Biology(米国)、AAT Bioquest, Inc.(米国)、Pestka Biomedical Laboratories, Inc.(米国)、Neuromics(米国)、BPS Bioscience, Inc.(米国)、BellBrook Labs(米国)、Profacgen(米国)、BMG LABTECH(ドイツ)、Hanugen Therapeutics(インド)、Altogen Labs(米国)、BioAgilytix(米国)。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 INCLUSIONS & EXCLUSIONS
1.3.2 MARKET SEGMENTATION AND REGIONAL SCOPE
1.3.3 YEARS CONSIDERED
1.3.4 CURRENCY CONSIDERED
1.4 STAKEHOLDERS
1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION
2.2.1 GLOBAL MARKET ESTIMATION (BOTTOM-UP APPROACH)
2.2.2 INSIGHTS FROM PRIMARY EXPERTS
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
2.3 MARKET GROWTH RATE PROJECTIONS
2.4 DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RISK ANALYSIS
2.7 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN CELL-BASED ASSAYS MARKET
4.2 NORTH AMERICA: CELL-BASED ASSAYS MARKET, BY END USER AND COUNTRY (2024)
4.3 CELL-BASED ASSAYS MARKET, BY OFFERING, 2024
4.4 CELL-BASED ASSAYS MARKET, BY END USER, 2024
4.5 CELL-BASED ASSAYS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Growing demand for drug discovery & development and increasing preference for cell-based assays in drug discovery
5.2.1.2 Government support and funding for cell-based research
5.2.1.3 Growing efforts to curtail animal-based studies
5.2.1.4 Rising prevalence of cancer
5.2.1.5 Alliances to accelerate innovations in drug discovery
5.2.2 RESTRAINTS
5.2.2.1 High cost of instruments and restrictions imposed by product end-user licenses for reagents
5.2.2.2 Lack of standardization of protocols used in cell-based assays
5.2.3 OPPORTUNITIES
5.2.3.1 Growing applications of cell-based assays in chronic diseases and personalized medicine
5.2.3.2 Growth opportunities in emerging economies
5.2.3.3 Rising adoption of AI in drug discovery and cell analysis
5.2.4 CHALLENGES
5.2.4.1 Complexities in assay designs
5.2.4.2 Shortage of skilled professionals
5.3 TECHNOLOGY ANALYSIS
5.3.1 KEY TECHNOLOGIES
5.3.1.1 Flow cytometry
5.3.1.2 High-throughput screening
5.3.1.3 High-content screening
5.3.1.4 Label-free detection
5.3.2 COMPLEMENTARY TECHNOLOGIES
5.3.2.1 Artificial intelligence and machine learning
5.3.3 ADJACENT TECHNOLOGIES
5.3.3.1 Nanotechnology
5.4 VALUE CHAIN ANALYSIS
5.5 PRICING ANALYSIS
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2021-2024
5.5.2 AVERAGE SELLING PRICE OF CELL-BASED ASSAYS, BY REGION, 2024
5.6 ECOSYSTEM ANALYSIS
5.6.1 RAW MATERIAL VENDORS
5.6.2 PRODUCT/SERVICE VENDORS
5.6.3 END USERS
5.6.4 REGULATORY BODIES
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.8 PATENT ANALYSIS
5.8.1 NUMBER OF PATENTS APPLIED AND GRANTED, BY DOCUMENT TYPE, 2014-2025
5.9 KEY CONFERENCES & EVENTS, 2025-2026
5.10 TARIFF AND REGULATORY LANDSCAPE
5.10.1 TARIFF RELATED TO CELL-BASED ASSAY PRODUCTS
5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.10.3 REGULATORY FRAMEWORK
5.10.3.1 North America
5.10.3.2 Europe
5.10.3.3 Asia Pacific
5.10.3.4 Rest of the World
5.11 PORTER'S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY STAKEHOLDERS & BUYING CRITERIA
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.12.2 BUYING CRITERIA
5.13 INVESTMENT AND FUNDING SCENARIO
5.14 TRADE ANALYSIS
5.14.1 IMPORT DATA
5.14.2 EXPORT DATA
5.15 IMPACT OF AI/GENERATIVE AI ON CELL-BASED ASSAYS MARKET
5.16 IMPACT OF 2025 US TARIFF ON CELL-BASED ASSAYS MARKET
5.16.1 INTRODUCTION
5.16.2 KEY TARIFF RATES
5.16.3 PRICE IMPACT ANALYSIS
5.16.4 IMPACT ON COUNTRY/REGION
5.16.4.1 US
5.16.4.2 Europe
5.16.4.3 Asia Pacific
5.16.5 IMPACT ON END-USE INDUSTRIES
5.16.5.1 Pharmaceutical & biotech companies
5.16.5.2 Contract research organizations (CROs)
5.16.5.3 Academic & research institutes
6 CELL-BASED ASSAYS MARKET, BY OFFERING
6.1 INTRODUCTION
6.2 CONSUMABLES
6.2.1 REAGENTS
6.2.1.1 High demand for reagents in research applications to propel market growth
6.2.2 ASSAY KITS
6.2.2.1 Reporter gene assays
6.2.2.1.1 Versatility of reporter gene assays and widespread applications to fuel growth
6.2.2.2 Cell growth assays
6.2.2.2.1 Rising use of cell viability and cell proliferation assays for assessing cell growth to boost market
6.2.2.3 Secondary messenger assays
6.2.2.3.1 Adoption of secondary messenger assays for cell signaling studies to fuel growth
6.2.2.4 Cell death assays
6.2.2.4.1 Importance of cell death quantification in drug development to favor growth
6.2.2.5 Other assay kits
6.2.3 MICROPLATES
6.2.3.1 Demand for microplates in assay development to drive market
6.2.4 CELL LINES
6.2.4.1 Immortalized cell lines
6.2.4.1.1 Wide use of immortalized cell lines to boost market
6.2.4.2 Primary cell lines
6.2.4.2.1 Advantages in drug development, preclinical research, and other applications to propel market
6.2.4.3 Stem cell lines
6.2.4.3.1 Rising use in tissue and disease models to fuel adoption
6.2.5 PROBES & LABELS
6.2.5.1 Growing need for effective cell labeling to boost demand
6.2.6 OTHER CONSUMABLES
6.3 INSTRUMENTS
6.3.1 AUTOMATION IN INSTRUMENTS TO DRIVE SEGMENTAL GROWTH
6.4 SERVICES
6.4.1 GROWING NUMBER OF CROS PROVIDING DRUG DISCOVERY AND SCREENING SERVICES TO ACCELERATE GROWTH
6.5 SOFTWARE
6.5.1 INCREASING ADOPTION OF SOFTWARE FOR EFFICIENT DATA ANALYSIS TO DRIVE GROWTH
7 CELL-BASED ASSAYS MARKET, BY TECHNOLOGY
7.1 INTRODUCTION
7.2 FLOW CYTOMETRY
7.2.1 WIDE USAGE OF FLOW CYTOMETRY IN CELL-BASED ASSAYS TO DRIVE MARKET
7.3 HIGH-THROUGHPUT SCREENING
7.3.1 INCREASING INVESTMENTS AND FUNDING FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH
7.4 LABEL-FREE DETECTION
7.4.1 GROWING ADOPTION OF ADVANCED TECHNOLOGIES TO DRIVE DEMAND
7.5 OTHER TECHNOLOGIES
8 CELL-BASED ASSAYS MARKET, BY APPLICATION
8.1 INTRODUCTION
8.2 DRUG DISCOVERY
8.2.1 TOXICITY STUDIES
8.2.1.1 Increasing demand for cell-based assays in toxicity testing to fuel growth
8.2.2 PHARMACOKINETIC STUDIES
8.2.2.1 Growing focus on ADME studies in pharmacokinetics to propel demand for cell-based assays
8.2.3 PHARMACODYNAMIC STUDIES
8.2.3.1 Advantages of cell-based assays in pharmacodynamics to propel growth
8.3 BASIC RESEARCH
8.3.1 INCREASING FUNDING BY GOVERNMENT INSTITUTES FOR BASIC RESEARCH TO DRIVE DEMAND FOR CELL-BASED ASSAY PRODUCTS & SERVICES
8.4 GENETIC STUDIES
8.4.1 INCREASING FUNDING FOR GENETIC RESEARCH TO DRIVE MARKET
8.5 OTHER APPLICATIONS
9 CELL-BASED ASSAYS MARKET, BY END USER
9.1 INTRODUCTION
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.2.1 GROWTH IN R&D EFFORTS TOWARD CELL-BASED ASSAYS IN PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTORS TO DRIVE MARKET
9.3 CONTRACT RESEARCH ORGANIZATIONS
9.3.1 GROWING PREFERENCE FOR OUTSOURCING TO DRIVE DEMAND FOR CELL-BASED ASSAYS IN CONTRACT RESEARCH
9.4 ACADEMIC & RESEARCH INSTITUTES
9.4.1 RISING FOCUS ON DEVELOPING ASSAYS FOR INNOVATIVE APPLICATIONS TO DRIVE MARKET
10 CELL-BASED ASSAYS MARKET, BY REGION
10.1 INTRODUCTION
10.2 NORTH AMERICA
10.2.1 MACROECONOMIC OUTLOOK
10.2.2 US
10.2.2.1 Established pharmaceutical and biotechnology sectors to drive market
10.2.3 CANADA
10.2.3.1 Increasing funding and investments to drive market
10.3 EUROPE
10.3.1 MACROECONOMIC OUTLOOK
10.3.2 GERMANY
10.3.2.1 To dominate cell-based assays market in Europe
10.3.3 UK
10.3.3.1 Growing cancer research funding to increase demand for cell-based assays
10.3.4 FRANCE
10.3.4.1 Growing biotechnology sector to drive market
10.3.5 ITALY
10.3.5.1 Growth of pharmaceutical industry to boost market
10.3.6 SPAIN
10.3.6.1 Rising research activity and increasing number of biotech companies to favor market growth
10.3.7 REST OF EUROPE
10.4 ASIA PACIFIC
10.4.1 MACROECONOMIC OUTLOOK
10.4.2 CHINA
10.4.2.1 Increasing R&D expenditure to favor market growth
10.4.3 JAPAN
10.4.3.1 Government initiatives for drug innovation to support market growth
10.4.4 INDIA
10.4.4.1 Increasing investments in R&D and funding for life science research to propel market
10.4.5 AUSTRALIA
10.4.5.1 Booming life science sector to propel market
10.4.6 SOUTH KOREA
10.4.6.1 Increasing strategic alliances to support market growth
10.4.7 REST OF ASIA PACIFIC
10.5 LATIN AMERICA
10.5.1 MACROECONOMIC OUTLOOK
10.5.2 BRAZIL
10.5.2.1 Brazil to hold largest share of Latin American market
10.5.3 MEXICO
10.5.3.1 Government support for biopharmaceutical production to support market growth
10.5.4 REST OF LATIN AMERICA
10.6 MIDDLE EAST
10.6.1 MACROECONOMIC OUTLOOK
10.6.2 GCC COUNTRIES
10.6.2.1 Saudi Arabia
10.6.2.1.1 Increasing R&D investments to drive market
10.6.2.2 UAE
10.6.2.2.1 Investments and support for biopharma sector to offer growth opportunities
10.6.2.3 Rest of GCC Countries
10.6.3 REST OF MIDDLE EAST
10.7 AFRICA
10.7.1 RISING NEED FOR EFFECTIVE DIAGNOSTICS TO SUPPORT MARKET GROWTH
10.7.2 MACROECONOMIC OUTLOOK
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL-BASED ASSAYS MARKET
11.3 REVENUE ANALYSIS, 2020-2024
11.4 MARKET SHARE ANALYSIS, 2024
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
11.5.5.1 Company footprint
11.5.5.2 Offering footprint
11.5.5.3 Technology footprint
11.5.5.4 Application Footprint
11.5.5.5 Region footprint
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
11.6.5.1 Detailed list of key startups/SMEs
11.6.5.2 Competitive benchmarking of key emerging players/startups
11.7 COMPANY VALUATION & FINANCIAL METRICS
11.8 BRAND/PRODUCT COMPARISON
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
11.9.2 DEALS
11.9.3 EXPANSIONS
12 COMPANY PROFILES
12.1 INTRODUCTION
12.2 KEY PLAYERS
12.2.1 DANAHER
12.2.1.1 Business overview
12.2.1.2 Products/Services offered
12.2.1.3 Recent developments
12.2.1.3.1 Deals
12.2.1.3.2 Expansions
12.2.1.4 MnM view
12.2.1.4.1 Key strengths
12.2.1.4.2 Strategic choices
12.2.1.4.3 Weaknesses & competitive threats
12.2.2 THERMO FISHER SCIENTIFIC INC.
12.2.2.1 Business overview
12.2.2.2 Products/Services offered
12.2.2.3 Recent developments
12.2.2.3.1 Deals
12.2.2.3.2 Expansions
12.2.2.3.3 Other developments
12.2.2.4 MnM view
12.2.2.4.1 Key strengths
12.2.2.4.2 Strategic choices
12.2.2.4.3 Weaknesses & competitive threats
12.2.3 MERCK KGAA
12.2.3.1 Business overview
12.2.3.2 Products/Services offered
12.2.3.3 Recent developments
12.2.3.3.1 Deals
12.2.3.3.2 Expansions
12.2.3.4 MnM view
12.2.3.4.1 Key strengths
12.2.3.4.2 Strategic choices
12.2.3.4.3 Weaknesses & competitive threats
12.2.4 BD
12.2.4.1 Business overview
12.2.4.2 Products/Services offered
12.2.4.3 Recent developments
12.2.4.3.1 Product launches
12.2.4.3.2 Deals
12.2.4.4 MnM view
12.2.4.4.1 Key strengths
12.2.4.4.2 Strategic choices
12.2.4.4.3 Weaknesses & competitive threats
12.2.5 AGILENT TECHNOLOGIES, INC.
12.2.5.1 Business overview
12.2.5.2 Products/Services offered
12.2.5.3 Recent developments
12.2.5.3.1 Product launches
12.2.5.4 MnM view
12.2.5.4.1 Key strengths
12.2.5.4.2 Strategic choices
12.2.5.4.3 Weaknesses & competitive threats
12.2.6 LONZA
12.2.6.1 Business overview
12.2.6.2 Products/Services offered
12.2.6.3 Recent developments
12.2.6.3.1 Deals
12.2.6.3.2 Expansions
12.2.7 EUROFINS SCIENTIFIC
12.2.7.1 Business overview
12.2.7.2 Products/Services offered
12.2.7.3 Recent developments
12.2.7.3.1 Deals
12.2.8 CHARLES RIVER LABORATORIES
12.2.8.1 Business overview
12.2.8.2 Products/services offered
12.2.8.3 Recent developments
12.2.8.3.1 Service launches
12.2.8.3.2 Deals
12.2.9 BIO-RAD LABORATORIES, INC.
12.2.9.1 Business overview
12.2.9.2 Products/Services offered
12.2.10 REVVITY
12.2.10.1 Business overview
12.2.10.2 Products/Services offered
12.2.10.3 Recent developments
12.2.10.3.1 Product launches
12.2.11 SARTORIUS AG
12.2.11.1 Business overview
12.2.11.2 Products/Services offered
12.2.11.3 Recent developments
12.2.11.3.1 Expansions
12.2.12 CORNING INCORPORATED
12.2.12.1 Business overview
12.2.12.2 Products/Services offered
12.2.13 PROMEGA CORPORATION
12.2.13.1 Business overview
12.2.13.2 Products/Services offered
12.2.13.3 Recent developments
12.2.13.3.1 Product launches
12.2.14 CELL SIGNALING TECHNOLOGY, INC.
12.2.14.1 Business overview
12.2.14.2 Products/Services offered
12.2.15 ENZO BIOCHEM INC.
12.2.15.1 Business overview
12.2.15.2 Products/Services offered
12.2.15.3 Recent developments
12.2.15.3.1 Expansions
12.2.16 CARNA BIOSCIENCES, INC.
12.2.16.1 Business overview
12.2.16.2 Products/Services offered
12.2.17 INTERTEK GROUP PLC
12.2.17.1 Business overview
12.2.17.2 Products/services offered
12.2.17.3 Recent developments
12.2.17.3.1 Expansions
12.2.18 BICO
12.2.18.1 Business overview
12.2.18.2 Products/Services offered
12.3 OTHER PLAYERS
12.3.1 CELL BIOLABS, INC.
12.3.2 REACTION BIOLOGY
12.3.3 AAT BIOQUEST, INC.
12.3.4 PESTKA BIOMEDICAL LABORATORIES, INC.
12.3.5 NEUROMICS
12.3.6 BPS BIOSCIENCE, INC.
12.3.7 BELLBROOK LABS
12.3.8 PROFACGEN
12.3.9 BMG LABTECH GMBH
12.3.10 HANUGEN THERAPEUTICS
12.3.11 ALTOGEN LABS
12.3.12 BIOAGILYTIX LABS
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
